cyp4a

CYP4A11 CYP4F2-IN-1 is a cytochrome P450 (CYP) 4A11 and CYP4F2 inhibitor, applicable for research on kidney, cardiovascular, and cerebrovascular diseases.

CYP4A11 CYP4F2-IN-2 (compound 15) serves as an orally administered inhibitor targeting CYP4A11 4F2, exhibiting IC50 values of 120 nM and 220 nM, respectively. This compound effectively suppresses 20-HETE production within the rat kidney and shows promise in mitigating the progression of diabetic nephropathy and autosomal dominant polycystic kidney disease [1].

CAY10434 is an active inhibitor of CYP4A hydroxylase with an IC50 value of 8.8 nM in human kidney microsomal test. The maximum contractile value (Emax) of CAY 10434 was 6764 mg in improving the contractile process of angiotensin II.

CAY10462 (CTK8E8405) is an effective and selective inhibitor of the 20-HETE synthase CYP4A11 with an IC50 of 8.8 nM. CAY10462 exhibits nearly 200 times less potent for 1A, 1C, and 3A CYP450 enzymes.

ε-Viniferin (epsilon-Viniferin) a dimer of resveratrol, shows the inhibitory effects of epsilon-viniferin on human CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A activities.

1-Deoxysphingosine (m18:1(14Z)) is an unconventional sphingolipid featuring a (14Z) double bond at the n-4 position, synthesized when serine palmitoyltransferase combines palmitoyl-CoA with alanine, not serine, during sphingolipid production. Unlike typical sphingolipids, it lacks the essential C1-hydroxyl group for standard degradation but undergoes metabolism by cytochrome P450 (CYP) subfamilies CYP4A and CYP4F in MEF cells.